[go: up one dir, main page]

WO2008021250A3 - Compositions and methods for modulating apoptosis in cells over-expressing bcl-2 family member proteins - Google Patents

Compositions and methods for modulating apoptosis in cells over-expressing bcl-2 family member proteins Download PDF

Info

Publication number
WO2008021250A3
WO2008021250A3 PCT/US2007/017815 US2007017815W WO2008021250A3 WO 2008021250 A3 WO2008021250 A3 WO 2008021250A3 US 2007017815 W US2007017815 W US 2007017815W WO 2008021250 A3 WO2008021250 A3 WO 2008021250A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
family member
compositions
cells over
modulating apoptosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/017815
Other languages
French (fr)
Other versions
WO2008021250A2 (en
Inventor
Jay Jie-Qiang Wu
David M Hockenbery
Ling Wang
Jianxin Guo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VM DISCOVERY Inc
Fred Hutchinson Cancer Center
Original Assignee
VM DISCOVERY Inc
Fred Hutchinson Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VM DISCOVERY Inc, Fred Hutchinson Cancer Center filed Critical VM DISCOVERY Inc
Publication of WO2008021250A2 publication Critical patent/WO2008021250A2/en
Anticipated expiration legal-status Critical
Publication of WO2008021250A3 publication Critical patent/WO2008021250A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to compounds for modulating apoptosis in cells over expressing Bcl-2 Family member proteins. The present invention also relates to pharmaceutical compositions containing these compounds, and methods of using the compounds.
PCT/US2007/017815 2006-08-10 2007-08-10 Compositions and methods for modulating apoptosis in cells over-expressing bcl-2 family member proteins Ceased WO2008021250A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83691806P 2006-08-10 2006-08-10
US60/836,918 2006-08-10

Publications (2)

Publication Number Publication Date
WO2008021250A2 WO2008021250A2 (en) 2008-02-21
WO2008021250A3 true WO2008021250A3 (en) 2009-04-02

Family

ID=39082642

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/017815 Ceased WO2008021250A2 (en) 2006-08-10 2007-08-10 Compositions and methods for modulating apoptosis in cells over-expressing bcl-2 family member proteins

Country Status (1)

Country Link
WO (1) WO2008021250A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2194783T1 (en) * 2007-08-10 2017-12-29 Vm Discovery, Inc. Compositions and methods for apoptosis modulators
WO2011041731A2 (en) 2009-10-02 2011-04-07 Fred Hutchinson Cancer Research Center Method of inhibiting bcl-2-related survival proteins
WO2011041737A2 (en) 2009-10-02 2011-04-07 Fred Hutchinson Cancer Research Center Gain-of-function bcl-2 inhibitors
CA2794112A1 (en) * 2010-04-06 2011-10-13 Brigham Young University Antimetastatic compounds
CA2803687C (en) 2010-07-20 2019-04-30 Vestaron Corporation Insecticidal triazines and pyrimidines
JP5955531B2 (en) * 2011-11-07 2016-07-20 千葉県 Anticancer drug
CN103224466A (en) * 2013-04-15 2013-07-31 北京大学 Compound with beta-secretase inhibition function, its preparation method and application
WO2016135138A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135139A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135137A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135140A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003054A1 (en) * 1993-07-23 1995-02-02 Lxr Biotechnology Inc. Methods of treating apoptosis and associated conditions
US5807880A (en) * 1993-09-30 1998-09-15 Yamanouchi Pharmaceutical Co., Ltd. Azole derivative and pharmaceutical composition thereof
WO2005033048A2 (en) * 2003-09-29 2005-04-14 The Johns Hopkins University Wnt pathway antagonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003054A1 (en) * 1993-07-23 1995-02-02 Lxr Biotechnology Inc. Methods of treating apoptosis and associated conditions
US5807880A (en) * 1993-09-30 1998-09-15 Yamanouchi Pharmaceutical Co., Ltd. Azole derivative and pharmaceutical composition thereof
WO2005033048A2 (en) * 2003-09-29 2005-04-14 The Johns Hopkins University Wnt pathway antagonists

Also Published As

Publication number Publication date
WO2008021250A2 (en) 2008-02-21

Similar Documents

Publication Publication Date Title
WO2008021250A3 (en) Compositions and methods for modulating apoptosis in cells over-expressing bcl-2 family member proteins
WO2009099641A3 (en) Stabilized protein compositions
WO2007084321A3 (en) Antibodies to ox-2/cd200 and uses thereof
WO2008133722A3 (en) Anti human sclerostin antibodies
WO2011047087A3 (en) Protein detection via nanoreporters
WO2007127841A3 (en) Compositions and methods of preparation thereof
EP1984517B8 (en) Methods for modulating mannose content of recombinant proteins
WO2009155001A3 (en) Wnt protein signalling inhibitors
WO2009056631A3 (en) Molecules and methods for modulating complement component
WO2007047207A3 (en) 5-lipoxygenase-activating protein (flap) inhibitors
WO2007056021A3 (en) 5-lipoxygenase-activating protein (flap) inhibitors
WO2008060705A8 (en) Anti-dll4 antibodies and methods using same
MX2009004714A (en) 3-aminocarbonyi-substituted fused pyrazolo-derivatives as protein kinase modulators.
WO2010055082A3 (en) New crystal form of sunitinib malate
WO2008155061A3 (en) Cosmetic preparations containing hydrocarbons
WO2007056228A3 (en) 5-lipoxygenase-activating protein (flap) inhibitors
CA2705357C (en) Formulations for taci-immunoglobulin fusion proteins
WO2007130824A3 (en) Fused heterocylic compounds and their use as mglur5 modulators
WO2008011603A3 (en) Modulating notch1 signaling pathway for treating neuroendocrine tumors
WO2009071689A3 (en) 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
WO2007130697A3 (en) Anti-ephb4 antibodies and methods using same
WO2007130825A3 (en) Fused heterocyclic compounds and their use as mglur5 modulators
WO2007130822A3 (en) Mglur5 modulators iii
WO2007127506A8 (en) Anti-ephrinb2 antibodies and methods using same
IL186258A0 (en) Chimeric proteins, their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07836721

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07836721

Country of ref document: EP

Kind code of ref document: A2